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Stringent complete remission (sCR) of acute myeloid leukemia is defined as normal
hematopoiesis after therapy. Less sCR, including non-sCR, was introduced as insufficient
blood platelet, neutrophil, or erythrocyte recovery. These latter characteristics were defined
retrospectively as postremission transfusion dependency and were suggested to be of
prognostic value. In the present report, we evaluated the prognostic impact of achieving
sCR and non-sCR in the Danish National Acute Leukaemia Registry, including 769 patients
registered with classical CR (ie, ,5% blasts in the postinduction bone marrow analysis).
Individual patients were classified as having sCR (n 5 360; 46.8%) or non-sCR (n 5 409;
53.2%) based on data from our national laboratory and transfusion databases. Survival
analysis revealed that patients achieving sCR had superior overall survival (hazard ratio
[HR], 1.34; 95% confidence interval [CI], 1.10-1.64) as well as relapse-free survival
(HR, 1.25; 95% CI, 1.03-1.51) compared with those with non-sCR after adjusting for
covariates. Cox regression analysis regarding the impact of the stringent criteria for
blood cell recovery identified these as significant and independent variables. In
conclusion, this real-life register study supports the international criteria for response
evaluation on prognosis and, most importantly, documents each of the 3 lineage
recovery criteria as contributing independently.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignant clonal disorder, with acquired genetic
lesions of hematopoietic stem cells.1,2 In Denmark, approximately 250 patients are diagnosed with AML
each year, which corresponds to an incidence rate of 5.4 per 100 000 persons per year.3,4 The
cumulative 5-year survival is 17%.4 Despite AML being a highly malignant disease, it is potentially curable
if patients can tolerate and respond to intensive treatment. Curative treatment requires initial induction
chemotherapy, with the goal of achieving complete remission (CR). The prognostic value of achieving
CR is well known.5,6
By international standards, since 2003, stringent CR (sCR) has been defined as ,5% blasts in the
bone marrow, absence of blasts with Auer rods, and absence of extramedullary disease combined
with neutrophil counts .1.0 3 109/L, platelet counts .100 3 109/L, and independence from red
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cell transfusions.5,7,8 Patients with ,5% blasts in the bone marrow
who do not fulfill all the criteria for CR are categorized as having non-
sCR. Non-sCR is similar to CR but with incomplete recovery (CRi),
defined as CR with residual neutropenia or thrombocytopenia.5,8
However, CRi does not include the possibility of a patient having
anemia and a persistent need for red blood cell transfusions; hence,
the term non-sCR is used in this report.
Several studies show that sCR is associated with better outcomes in
terms of both overall survival (OS) and relapse-free survival (RFS)
compared with CRi.7,9-12 Such findings suggest that distinguishing
between sCR and other degrees of CR is of clinical value when
evaluating treatment response. However, most studies are limited by
excluding independence from red cell transfusions as a criterion for
achieving sCR, and therefore, the prognostic impact of sCR is unclear.
The Danish National Acute Leukaemia Registry (DNLR) includes all
Danish patients diagnosed with AML since January 1, 2000. It
contains information regarding prognostic factors, treatment
regimens, and outcomes, including patients’ remission status after
induction therapy. In parallel, we have national patient-centered
databases regarding blood values and transfusions identified by civil
registration numbers. The goal of the present study was to confirm
the prognostic impact of sCR compared with non-sCR in a
nationwide cohort of patients with AML.
Materials and methods
Registries: an epidemiological source of high quality
A keystone of this study was the use of population-based registries.
The study population was generated from the DNLR. This registry
and the quality of its data have been described in detail in a prior
study.3 In brief, the DNLR includes 99% of patients with AML
diagnosed in Denmark and covers information on intention of
treatment (palliation or remission induction), type and dose of
chemotherapy, treatment response, and outcome (ie, vital status).
We combined information from different registries using the civil
registration numbers of study participants. The civil registration
number is a unique personal identification number given to all
Danish inhabitants at birth or immigration, which unambiguously
records linkage.13,14 In 1997, the Danish National Pathology
Registry was established. It contains data on all pathological tests
performed in Denmark (eg, dates and results of bone marrow
biopsies). The information in the registry is reported by all departments
of pathology and is mandatory. As for the other registries, the data are
linked to the civil registration numbers.15,16 The Danish Transfusion
Registry contains information concerning transfusion data for all
patients receiving transfusions in Denmark. Information includes the
date and type of transfusion and the civil personal registration number
of the recipient.17
Study population and classification of CR
Patients fulfilling the following criteria were included in this study:
age $18 years; diagnosed with AML, excluding acute promyelo-
cytic leukemia, from 1 January 2000 to 31 December 2010; and
selected for intensive therapy, defined as a remission-induction
regimen with a backbone of standard to high dose of cytarabine
($200-400 mg/m2 per day) in combination with an anthracycline or
anthracycline-related compound, with achievement of classical CR
after first or second induction therapy. We evaluated the quality of
the CR as proposed by the International Working Group.5,8 Patients
fulfilling all CR criteria (ie,,5% blasts in the bone marrow, absence
of blasts with Auer rods, and absence of extramedullary disease
combined with neutrophil counts .1.0 3 109/L, platelet counts
.100 3 109/L, and independence from red cell transfusions5,7,8)
were categorized as sCR. Patients with ,5% blasts in the bone
marrow but not fulfilling all criteria (ie, having insufficient blood
platelet, neutrophil, or erythrocyte recovery) were categorized as
non-sCR. Evaluation of pathology was based on data gathered from
the Danish National Pathology Registry. Transfusion history data
were acquired from the Danish Transfusion Registry, and neutrophil
and platelet count data were collected from the various depart-
ments of hematology and departments of clinical biochemistry in
Denmark using primarily LABKA (laboratory information system).18
We defined day 0 as the date of bone marrow aspiration (ie, the day
of treatment evaluation) and defined a time period in which the
patients with sCR did not receive red blood cell transfusions from
day 11 until the first day of the next treatment cycle. Patients not
receiving red blood cell transfusions from day11 and forward were
classified as being transfusion independent. We strived to collect
data concerning blood neutrophil and platelet counts at day 0;
however, this was not possible for all patients, so we expanded the
timespan for these values from day 23 to day 17.
Statistical analysis
The distributions of demographic and clinical characteristics as well



















Figure 1. The patient cohort and defined study population. Flowchart
describing the postinduction, classical CR cohort and final study population. In total,
832 patients met all inclusion criteria. Because of missing data regarding blood
samples in LABKA and patients’ transfusion history, the final study population
included 769 patients who were included in the population analyzed in the present
study. APL, acute promyelocytic leukemia.
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groups were compared using Pearson’s x2 test and Fisher’s exact
test for categorical variables. Mann-Whitney U test was used for
continuous variables.
RFS for each patient was defined as the time from the classical CR
response to AML relapse, death resulting from any cause, or
censoring for patients alive without relapse at the time of last follow-
up and registration. OS was defined as the time from CR response
to death resulting from any cause or censoring. RFS and OS curves
were computed using the Kaplan-Meier method, and differences
between groups were tested using the log-rank test. The
association between groups (sCR and non-sCR) and outcomes
(OS and RFS) were evaluated using crude and adjusted Cox
proportional hazards regression analyses, including 769 patients in
the multivariable analyses. Adjustment were performed for age, sex,
World Health Organization performance score at diagnosis,
leukocyte count at diagnosis, CR as response after first or second
induction therapy, and cytogenetic risk group. Hazard ratios (HRs)
with 95% confidence intervals (CIs) were calculated. Throughout
the analyses, 95% CIs were reported and used if estimated results
were statistically significant. All data were analyzed using Stata/MP
13.1 (StataCorp, College Station, TX).
Ethics
This study was approved by the Danish Data Protection Agency
(2008-58-0028) and the Danish Health Authority.
Results
Patient characteristics and outcome assignment
In total, 832 patients with AML fulfilled the inclusion criteria, as
illustrated in Figure 1. We retrieved transfusion data from the
Table 1. Demographic and clinical characteristics of the study population in total, and assigned according to degree of CR (sCR or non-sCR)
Characteristic
All (N 5 769) sCR (n 5 360) Non-sCR (n 5 409)
N % N % N %
Age, y
Median (IQR) 56.6 (45.4-65.3) 39.3 54.5 (43.4-64.0) 35.3 58.6 (47.2-65.7) 42.8
$60 302 127 175
Sex
Male 406 52.8 180 50.0 226 55.3
Female 363 47.2 180 50.0 183 44.7
Year of diagnosis
2000-2002 199 25.9 66 18.3 133 32.5
2003-2010 570 74.1 294 81.7 276 67.5
WHO performance score at diagnosis
,2 647 84.1 306 85.0 341 83.4
$2 122 15.9 54 15.0 68 16.6
AML classification
De novo 638 83.0 311 86.4 327 80.0
Secondary* 105 13.7 38 10.6 67 16.4
Therapy related 26 3.4 11 3.1 15 3.7
Cytogenetic risk group
Favorable 49 5.2 20 5.6 20 4.9
Intermediate 554 72.0 258 71.7 296 72.4
Unfavorable 104 13.5 58 16.1 46 11.2
Missing 71 9.2 24 6.7 47 11.5
Characteristics at time of diagnosis, median (IQR)
Bone marrow blast count, % 55 (33-80) 60 (35-80) 51 (32-80)
Blast count blood, % 29 (9-65) 28 (8-70) 30 (4-59)
Leukocytes, 3 109/L 10.8 (2.4-44.7) 11.1 (2.8-42.8) 9.7 (2.2-46)
Platelets, 3 109/L 54 (30-103) 63 (33-122.5) 49 (25-86)
Days between the first day of treatment and CR
evaluation (IQR)
31 (27-35) 30 (27-35) 31 (27-37)
Days at risk for RBC transfusion (IQR)† 8 (6-13) 7 (6-13) 8 (6-12)
IQR, interquartile range; RBC, red blood cell; WHO, World Health Organization.
*Defined as AML in patients with prior hematological disease predisposing for AML.
†Days between bone marrow evaluation and the first day of following treatment.
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Danish Transfusion Registry for 808 patients (97.6%) and blood platelet
and neutrophil counts from LABKA for 769 patients (92.4%).
Table 1 lists baseline information regarding patient characteristics
and classification. A total of 360 (46.8%) of 769 patients were
classified as having sCR and 409 (53.2%) of 769 as having non-
sCR.
We observed that 678 patients with AML (88.2%) were in CR
after their first induction regimen, of whom 310 (45.7%) were
classified as achieving sCR and 368 (54.3%) as achieving non-
sCR. A total of 91 patients (11.8%) were in CR after the second
induction regimen, of whom 50 (54.9%) were classified as
achieving sCR and 41 (45.1%) as achieving non-sCR. In total,
525 patients (68.4%) died after CR, of whom 221 (42.1%) had
achieved sCR and 304 (57.9%) had achieved non-sCR. The
median OS was 3.4 years (range, 1.3-7.7 years) for those
achieving sCR and 2.0 years (range, 0.9-7.3 years) for those
achieving non-sCR. Furthermore, 333 patients experienced
postremission relapse, of whom 152 (45.7%) were classified as
achieving sCR and 181 (54.3%) as achieving non-sCR on day 0.
Assignment of non-sCR according to each of the 3 lineage
recovery criteria is presented as a Venn diagram in Figure 2,
illustrating heterogeneous classifications. Red blood cell transfu-
sions alone classified 35 patients (8.6%), incomplete neutrophil
recovery alone classified 160 patients (39.1%), and incomplete
platelet recovery alone classified 61 patients (14.9%). The
remaining patients were classified as non-sCR as a result of a
combination of $2 criteria not fulfilled.
OS and RFS
Figure 3A-B shows the OS and RFS Kaplan-Meier curves for the
sCR and non-sCR groups. Patients who achieved sCR had
significantly better outcomes compared with those with non-sCR.
As summarized in Table 2, the adjusted HR was 1.34 (95% CI,
1.10-1.64) for OS and 1.25 (95% CI, 1.03-1.51) for RFS for sCR
compared with non-sCR. Incomplete platelet, neutrophil, and
erythrocyte (red blood cell transfusions) recovery were each
independent risk factors for inferior outcomes (Table 3). That is,
each of the consensus criteria was associated with a statistically
significantly higher risk of death or relapse of AML. This association
persisted after further adjustment for AML classification (ie, AML de
novo, secondary AML, or therapy-related AML; data not shown).
Secondary analysis (data not shown) showed no significant
difference between the sCR and non-sCR groups regarding the
frequency of undergoing hematopoietic stem-cell transplantation.
Discussion
The present study demonstrates and supports that patients with
AML who achieve sCR have statistically significantly higher OS
and RFS compared with patients who do not achieve sCR (ie,
those achieving non-sCR).7,9,11,12 Moreover, our study validates
the significance of each of the 3 lineage recovery criteria for
achieving sCR, providing evidence for the use of all these criteria
in clinical practice. Several studies have shown that patients with
AML who achieve sCR have a better prognosis than patients
who do not.7,9,11,12 However, these studies differ by various














Figure 2. Absolute and relative numbers of patients with insufficient
3-lineage recovery. Venn diagram illustrating analysis of international consensus
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Figure 3. OS and RFS. Kaplan-Meier estimates for OS (A) and RFS (B) presented
with 95% CIs and log-rank test for 769 patients at risk. (A) Probability of OS in
patients who achieved sCR or non-sCR. (B) Probability of RFS of patients who
achieved sCR or non-sCR.
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We investigated the impact of each single criterion on the
prognostic outcome at the time that patients achieved ,5%
blasts in bone marrow and documented that each criterion was
associated with OS and RFS. This finding is in agreement with a
study by de Greef et al,19 in which the CR criteria as proposed by
Cheson et al5 were verified. Both platelet and neutrophil recovery had
a high impact on prognosis regarding OS (HR, 2.17; P 5 .002
and HR, 1.41; P 5 .090, respectively), comparable to our results.
We found that all sCR criteria had a high impact on prognosis
(Table 3). Incomplete recovery of neutrophils was the criterion
most likely to interact with the remaining criteria, as shown in
the Venn diagram (Figure 3). Unfortunately, de Greef et al19 did
not include information regarding red blood cell transfusion
dependency.
To the best of our knowledge, no prior study has documented the
expected prognostic value of red blood cell transfusion de-
pendency in the evaluation of CR quality. Our study shows that
patients who are independent of red cell transfusions, in addition
to achieving platelet and neutrophil recovery, have an improved
prognosis.
Achievement of sCR is an important goal after induction
chemotherapy for AML. We found a positive association between
CR quality and risk of relapse, which indicates that inferior OS
related to non-sCR may be due to the relapse of AML and is
possibly caused by residual disease. The association persisted
after adjustment for type of AML (de novo, secondary, or therapy-
related AML). Furthermore, the association was not explained by
difference in rate of allogeneic bone marrow transplantation among
patients in sCR compared with non-sCR. We performed adjust-
ment for cytogenetic risk group, which did decrease the association
between degree of CR and RFS, supporting that cytogenetic risk
group may influence the chance of sCR; however, cytogenetic risk
group is probably not the only explanation, because the association
persisted (Table 3). We propose extended studies to enumerate
the level of minimal residual leukemic bone marrow blasts and
define sCR using advanced assays, with counting accuracy and
high specificity at the level of sensitivity.
The response criteria for patients with AML were developed
based on recovery of normal hematopoiesis by blood cell
regeneration and bone marrow assessment, which are relatively
insensitive analyses. Given the high rates and varying depths of
CRs seen with new treatment approaches, there is a clinical
need to define new response categories that can identify deeper
responses. Recent attempts have focused on identifying
residual tumor cells in the bone marrow using flow cytometry
or specific gene expression.20-22 Combining these new meth-
ods may define new response categories of minimal residual
disease negativity, which will allow for uniform reporting in the
precision medicine era.
Our large nationwide population-based cohort study covers nearly
every patient with AML in Denmark fulfilling the inclusion criteria.
We were unable to retrieve a complete data set regarding blood cell
transfusion, platelets counts, or neutrophil counts on the date of
response evaluation (day 0) in only 63 (7.6%) of 832 patients (all
excluded). We do not think that missing information was associated
with the classification of sCR or non-sCR, and therefore, we do not
think that this biased our results.
In summary, the present survival analysis confirms that patients
achieving sCR have superior OS as well as RFS compared with
those with non-sCR when adjusted for covariates. Cox regression
analysis identified blood counts and transfusions as independent
variables. Therefore, red blood cell transfusion must not be ignored
when evaluating treatment response. Using a prospective ap-
proach, there is a clinical need to define sCR by exact values for
minimal residual leukemic blasts in the postinduction therapy bone
marrow analysis.
Table 3. Cox regression analysis regarding the impact of CR criteria
not met on OS and RFS
Non-sCR vs sCR
OS RFS
HR 95% CI HR 95% CI
Incomplete platelet recovery
Crude 1.81 1.49-2.20 1.68 1.39-2.04
Age and sex adjusted 1.61 1.32-1.97 1.56 1.28-1.89
Fully adjusted* 1.61 1.39-2.00 1.56 1.26-1.93
Fully adjusted including remaining CR criteria† 1.27 0.97-1.66 1.26 0.97-1.64
Incomplete neutrophil recovery
Crude 1.33 1.05-1.69 1.27 1.01-1.61
Age and sex adjusted 1.37 1.08-1.75 1.29 1.02-1.63
Fully adjusted* 1.48 1.14-1.92 1.39 1.08-1.79
Fully adjusted including remaining CR criteria† 1.38 1.05-1.79 1.31 1.01-1.69
No independence of red cell transfusion
Crude 1.50 1.19-1.89 1.33 1.06-1.67
Age and sex adjusted 1.41 1.11-1.78 1.28 1.01-1.61
Fully adjusted* 1.40 1.08-1.82 1.27 0.98-1.64
Fully adjusted including remaining CR criteria† 1.44 1.06-1.95 1.32 0.97-1.78
*Adjusted for age, sex, World Health Organization performance score at diagnosis,
leukocyte count at diagnosis, CR as response after first or second induction therapy, and
cytogenetic risk group.
†Adjusted for the abovementioned variables as well as the remaining sCR criteria
(ie, incomplete platelet recovery, incomplete neutrophil recovery, and no independence of
red cell transfusion).
Table 2. Cox regression analysis regarding the impact of CR





Age and sex adjusted 1.32 1.10-1.59
Fully adjusted* 1.34 1.10-1.64
RFS
Crude 1.28 1.08-1.53
Age and sex adjusted 1.23 1.03-1.47
Fully adjusted* 1.25 1.03-1.51
*Adjusted for age, sex, World Health Organization performance score at diagnosis,
leukocyte count at diagnosis, CR as response after first or second induction therapy, and
cytogenetic risk group.
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